Novo and Valo originally partnered in September 2023 in an agreement to develop up to 11 drugs. With the expanded agreement, Novo will collaborate with Valo to discover and develop up to 20 new treatments for obesity, type 2 diabetes, and cardiovascular diseases.

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial intelligence (AI) partnership aimed at discovering and developing up to 20 treatments for obesity,

Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and billions on the back end—to apply artificial intelligence to up to 20 programs.

Novo Nordisk has almost doubled the scale of an R&D alliance with Valo Health – a specialist in applying artificial intelligence to drug discovery – adding up to nine programmes to the original 11 covered in their original agreement.

Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI).

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic diseases, leveraging AI and extensive human datasets. The collaboration,

Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence.The deal extends an agreement signed in 2023 and will see Valo become eligible for increased payments and funding.Under the original deal, the companies agreed to develop up to 11 drug programs, primarily focused on cardiovascular disease, with Valo eligible to receive up to $2.7 billion in milestone payments, plus research and development funding and potential royalty payments.The new agreement set out Wednesday expands the scope to put a stronger focus on obesity and type 2 diabetes and includes near-term payments to Valo of up to $190 million.A further $4.6 billion in potential milestone payments will be made for up to nine new drug programs and Valo will also be eligible for more research and development funding and potential royalty payments.The companies will continue to use Valo’s drug discovery and development platform that uses patient data and AI to generate new insights and translate them into potential therapeutics.“We have already begun to realize the potential of combining the capabilities of Valo and Novo Nordisk to advance multiple AI-powered, human-centric programs, and we believe this partnership will help Novo Nordisk fulfill our ambition to expand the number of new drug programs we bring to the clinic,” said Marcus Schindler, executive vice president and chief scientific officer of Novo Nordisk.The Danish pharmaceutical giant recently reported disappointing results of a closely watched clinical trial testing an experimental anti-obesity treatment that the company hoped would be its next big weight-loss product.Write to Dominic Chopping at [email protected]

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss drug.

Denmark's Novo Nordisk on Wednesday announced an expansion of its collaboration with Valo Health to discover and develop novel treatments for obesity, type-2 diabetes, and cardiovascular disease. It has committed to a near-term payment of $190 million and the collaboration expects milestone payments of approximately $4.

The companies entered the agreement in 2023 to jointly advance as many as 11 drug programs, mainly targeting cardiovascular diseases. Under the terms, Valo was initially entitled to receive as much as $2.7 billion in milestone payments as well as R&D funding and royalty payments from Novo Nordisk.